Baseline socio-demographic characteristics of HPTN 063 female study participants by site.

<p>Baseline socio-demographic characteristics of HPTN 063 female study participants by site.</p

Associations of anticipated stigma, perceived community stigma, and perceived community norms with disclosure to sexual partners.

<p>Associations of anticipated stigma, perceived community stigma, and perceived community norms with disclosure to sexual partners.</p

Associations of female HPTN063 participant characteristics with disclosure to sexual partners.

<p>Associations of female HPTN063 participant characteristics with disclosure to sexual partners.</p

Sociodemographic, behavioral, and health characteristics of participants (N = 80).

<p>Sociodemographic, behavioral, and health characteristics of participants (N = 80).</p

Univariable and multivariable regressions of factors correlating with <80% electronic monitoring adherence.

<p>Less than 80% adherence was seen among 282 participants in 14.4% of study quarters. MEMS data were available for 4,357 of 4,463 (97.2%) study quarters.</p>a<p><i>n</i> (row %) or mean (SD).</p>*<p>Bold indicates <i>p</i><0.05.</p

Distribution of adherence by unannounced pill count and electronic monitoring.

<p>Distribution of adherence by unannounced pill count and electronic monitoring.</p

Enrollment characteristics of study participants.

<p>Complete data were available on all variables (<i>n</i> = 1,147) except for questions regarding unprotected sex in the prior month (missing in 3%), polygamy (<1%), and viral load (1%).</p>a<p>From the three sites from which the adherence substudy recruited.</p><p>n/a, not applicable.</p

Risk Factors of Time to Treatment Failure.

1<p>All adjusted models include treatment condition.</p><p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p

Baseline Participant Characteristics.

<p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p><p>Treatment: Once daily protease inhibitor + nucleoside reverse transcriptase inhibitors: atazanavir + didanosine-EC and emtricitabine.</p><p>Treatment: Once daily non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated emtricitabine-tenofovir-DF.</p><p>Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.</p

ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line = did not miss any pills; dashed line = missed any pills).

<p>ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line  =  did not miss any pills; dashed line  =  missed any pills).</p